ライフサイエンスコーパス: analgesics

1 r pain, and medications (eg, anxiolytics and analgesics).

2 problems are adequately treated with current analgesics.

3 hem prime targets for the development of new analgesics.

4 derlie mechanisms of pain suppression by new analgesics.

5 perative pain and consumption of opioids and analgesics.

6 more in patients without a regular need for analgesics.

7 nded include an opioid-antagonist and opiate analgesics.

8 To compare the efficacy of 4 oral analgesics.

9 targeting this system hold promise as novel analgesics.

10 rug discovery efforts towards novel visceral analgesics.

11 It remains poorly treated with current analgesics.

12 m-based approaches in the development of new analgesics.

13 ts, antibiotics, diabetes agents, and opioid analgesics.

14 es as safe and potentially abuse-free opioid analgesics.

15 d analgesia and total doses of sedatives and analgesics.

16 2.3 channels as potential targets for opioid analgesics.

17 r syndrome and discharged to be treated with analgesics.

18 Mg(2+) leads to increased efficacy of opioid analgesics.

19 tential for the generation of new classes of analgesics.

20 ent selective antagonists of Nav1.7 are weak analgesics.

21 nistration (FDA) for new approvals of opioid analgesics.

22 sible for the efficacy of the most effective analgesics.

23 been proposed as an improved class of opioid analgesics.

24 g therapeutic advantage over standard opioid analgesics.

25 er somniferum, is one of the strongest known analgesics.

26 class of drugs known collectively as opioid analgesics.

27 progress in controlling the abuse of opioid analgesics.

28 m-guided stepped care approach to optimizing analgesics.

29 heral neurons, are being pursued as possible analgesics.

30 t satisfaction, and use of opioids and other analgesics.

31 , which is not readily relieved by available analgesics.

32 psis, with animals receiving antibiotics and analgesics.

33 severe pain that needs treatment with opioid analgesics.

34 ght be a novel target for the development of analgesics.

35 egional techniques with opioid and nonopioid analgesics.

36 nagement of drug withdrawal, and as sedative analgesics.

37 ay be a useful new approach to develop novel analgesics.

38 cid (aspirin) is one of the most widely used analgesics.

39 been considered to be promising nonaddictive analgesics.

40 gs such as beta-blockers, antipsychotics and analgesics.

41 e the need for standard postoperative opioid analgesics.

42 ry drugs (NSAIDs) are effective, widely used analgesics.

43 cts, accidental poisonings) involving single analgesics.

44 increased the antiallodynic effects of all 3 analgesics.

45 gnificant increase in deaths involving other analgesics.

46 nfront issues related to pain and the use of analgesics.

47 polypeptide antibiotics, preservatives, and analgesics.

48 on of possible substitution effects by other analgesics.

49 agonists represent important targets for new analgesics.

50 analog resiniferatoxin are well known potent analgesics.

51 y for the production of longer acting opioid analgesics.

52 ifferent avenue for the development of novel analgesics.

53 ew decades, few advances have been made with analgesics.

54 ceramide metabolic-to-COX-2 pathway as novel analgesics.

55 muli and, hence, a potential drug target for analgesics.

56 his receptor and improve upon current opioid analgesics.

57 ry was driven by the search for nonaddicting analgesics.

58 tional strategies for screening of potential analgesics.

59 ts who have not responded to oral or topical analgesics.

60 eful strategy for obtaining potent and safer analgesics.

61 S1PR1 antagonists as a class of nonnarcotic analgesics.

62 s a serious adverse event produced by opioid analgesics.

63 erest target for the discovery of non-opioid analgesics.

64 g lead in the development of next generation analgesics.

65 viate OIH, a serious adverse event of opioid analgesics.

66 as a high interest target for developing new analgesics.

67 ds to serve as potential nonaddictive opioid analgesics.

68 quinoline alkaloid (BIA) precursor to opioid analgesics.

69 eptor neurons are attractive targets for new analgesics.

70 fferent opioid and acetaminophen combination analgesics.

71 ic pain states that are refractive to opioid analgesics.

72 were age 1.014(95% CI: 1.006-1.022), use of analgesics 1.461 (95% CI: 1.060-2.025), and use of herbs

73 IV reasons for admission: 1) alcohol(s), 2) analgesics, 3) antidepressants, 4) street drugs, 5) seda

74 and reduction or discontinuation of narcotic analgesics (55% of patients), as well as improvements in

75 Some antithrombotics, antibiotics, opioid analgesics, adrenergics, proton-pump inhibitors, nitrogl

76 pain measured by pain scores and the need of analgesics after 1 year of surgery.

77 s shown that patients may be over-prescribed analgesics after surgery.

78 To control for the confounding effects of analgesics, all patients received 650 mg acetaminophen f

79 These include analgesics, anaesthesia required for surgery, and the de

80 pioid receptor, the primary target of opioid analgesics and abused drugs.

81 Regular or frequent use of analgesics and acute antimigraine drugs can increase the

82 Systemic nonopioid analgesics and adjuvant analgesics may be prescribed to

83 t to the clinical community: anticoagulants, analgesics and buffers.

84 misuse and diversion of prescription opioid analgesics and heroin.

85 of low-dose opioids combined with nonopioid analgesics and in the treatment of opioid use disorder a

86 v) channel inhibitors are used clinically as analgesics and local anesthetics.

87 ts the therapeutic efficacy of morphine-like analgesics and mediates the long duration of kappa opioi

88 nd depression, employment status, and use of analgesics and nonsteroidal anti-inflammatory drugs at 1

89 Treatment of bone pain includes nonsteroidal analgesics and opiates; however, long-term use of these

90 ons for chronic complications include use of analgesics and physical therapy for treatment of avascul

91 diabetic neuropathy is poorly controlled by analgesics and requires high doses of opioids, triggerin

92 The use of analgesics and sedatives was assessed daily.

93 ysphoria is key to the development of better analgesics and to defining how the endogenous dynorphin

94 Age, use of analgesics and use of herbs increase the risk, albeit mi

95 eful strategy for obtaining potent and safer analgesics and were the basis for the selection of 14u a

96 l care practitioners prescribe sedatives and analgesics and, perhaps more broadly, how all medication

97 re admitted to the ICU and administered with analgesics and/or sedatives.

98 nd consists of adequate fluid resuscitation, analgesics, and monitoring.

99 th hip or knee OA, inadequate response to OA analgesics, and no radiographic evidence of prespecified

100 oped chronic abdominal pain requiring strong analgesics, and one in five suffered from severe abdomin

101 nnel enhancers were suggested as prospective analgesics, and targeting M channels specifically in per

102 of chronic pain is poorly managed by current analgesics, and there is a need for new classes of drugs

103 take the form of, for example, antibiotics, analgesics, anti-inflammatories or growth factors.

104 erent therapeutic classes (i.e. antibiotics, analgesics, anti-inflammatories, cardiovascular agents,

105 Treatment usually involves analgesics, anti-inflammatory drugs, and supportive care

106 tics, diuretics, beta blockers, anesthetics, analgesics, antiepileptics, antidepressants, and others)

107 le observed change in deaths involving other analgesics, apart from an increase in oxycodone poisonin

108 Opioid analgesics are commonly used in chronic pain management

109 rption, metabolism, and receptor affinity of analgesics are critical to a drug's efficacy is becoming

110 Topical analgesics are emerging as a valued multimodal analgesic

111 Because opiate analgesics are highly addictive substances, their use in

112 Opioid analgesics are powerful pain relievers; however, over ti

113 Although opioid analgesics are typically embraced as the mainstay of pha

114 Opioid-based analgesics are widely used for treating chronic pain, bu

115 al evidence still supports the use of opioid analgesics as the gold standard to treat cancer-related

116 Prescription of opioid analgesics at discharge.

117 ,026 (67%) reported having pain or requiring analgesics at initial assessment; of these 2,026 patient

118 This article describes the major opioid analgesics available for the treatment of cancer-related

119 Opioids are some of the most potent analgesics available.

120 postoperatively in pain response or need for analgesics between the study groups.

121 Opiates are potent analgesics but their clinical use is limited by side eff

122 lycine transporter 2, GlyT2, show promise as analgesics, but may be limited by their toxicity through

123 ily, are under active investigation as novel analgesics, but their modes of signaling are less well c

124 the potential to be effective, nonaddictive analgesics, but their therapeutic utility is greatly lim

125 Opioids are very effective analgesics, but they are also highly addictive.

126 des a rationale for an entirely new class of analgesics by inhibition of oxidative enzyme activity.

127 by increases in prescribing of several other analgesics (co-codamol, paracetamol, codeine, co-dydramo

128 raine attacks has been limited to the use of analgesics, combinations of analgesics with caffeine, er

129 mers has the potential to identify leads for analgesics devoid of adverse effects.

130 st functional activity could emerge as novel analgesics devoid of tolerance, dependence, and related

131 inal pain were defined as those using strong analgesics, diagnosed with chronic pain, or referred to

132 e pain is mainly empirical, involving potent analgesics, duct drainage by endoscopic or surgical mean

133 Furthermore, the consumption of analgesics during the postoperative week 1 was assessed.

134 influence of low-dose ketamine, one of three analgesics employed in the pre-hospital setting by the U

135 his review will focus on advances in topical analgesics, especially their role as an effective analge

136 risk of developing OUD and receiving opioid analgesics, even after accounting for comorbidities and

137 on that specific receptors for morphine-like analgesics exist, the search for endogenous ligands for

138 d focus on limiting supplies of prescription analgesics for abuse, including ADF technology, efforts

139 morphine and other opioids remain essential analgesics for alleviating pain.

140 wer adverse events compared with alternative analgesics for cancer pain?

141 Some 25 patients (4.2%) needed occasionally analgesics for chronic groin pain.

142 nvision a class of non-opioid nAChR-targeted analgesics for chronic pain.

143 ioids such as oxycodone are highly effective analgesics for clinical pain management, but their misus

144 l incision or positioning that required oral analgesics for longer than 3-4 days after surgery (five

145 t intratumoral androgen synthesis and act as analgesics for metastatic disease.

146 each of the two treatment groups did not use analgesics for pain control.

147 The prescribing of opioid analgesics for pain management-particularly for manageme

148 ) has continued to be treated primarily with analgesics for pain relief.

149 ciceptor signaling to the brain and serve as analgesics for persistent pain.

150 lated mimetics might serve as a new class of analgesics for preventing and treating neuropathic pain.

151 Opioids are commonly used as analgesics for severe pain, but their addictive potentia

152 ds hence represent a promising avenue toward analgesics for the dual treatment of acute and neuropath

153 outcomes of RCT/s comparing 2 or more opioid analgesics for the management of chronic pain were obtai

154 Opioids are effective analgesics for the management of moderate to severe canc

155 ectiveness of morphine and related mu opioid analgesics for the treatment of chronic inflammatory pai

156 further aid the development of peptide-based analgesics for the treatment of chronic pain.

157 Opioids are the most effective analgesics for the treatment of moderate to severe pain.

158 Hazard ratios (HRs) associated with use of analgesics for total incident hematologic malignancies a

159 encoded by Oprm1) agonists are the mainstay analgesics for treating moderate to severe pain.

160 o being the target of the potent neuropathic analgesics gabapentin and pregabalin (alpha2delta-1 and

161 nee osteoarthritis (OA) have been limited to analgesics, glucocorticoids, hyaluronic acid (HA) and a

162 Frequent use of analgesics has been associated with a higher risk of hea

163 for endogenous opioid neurotransmitters and analgesics, has been a major focus for drug discovery in

164 Efforts to improve safety of u-opioid analgesics have focused on agonists that show signaling

165 harmaceutical development pipeline lacks new analgesics, health-care professionals, patients and medi

166 Use of analgesics (HR, 1.22; 95% CI, 1.08 to 1.37), hypnotics/s

167 HR, 1.35; 95% CI, 1.03 to 1.76); and use of analgesics (HR, 1.33; 95% CI, 1.16 to 1.52), hypnotics/s

168 volved in brain-to-blood transport of opioid analgesics (i.e., morphine).

169 RGS proteins modulate the efficacy of opioid analgesics in a brain region- and agonist-selective fash

170 rmacological profile against existing opioid analgesics in assays not confounded by limited signal wi

171 Opioids are the most potent analgesics in clinical use; however, their powerful rewa

172 nto future therapies as antipruritics and/or analgesics in humans.

173 ls for preclinical assessment of prospective analgesics in inflammatory pain states.

174 c intractable insomnia where the traditional analgesics in PCA were replaced with dexmedetomidine (De

175 on to being on average inferior to NSAIDs as analgesics in postsurgical dental pain, opioids produce

176 cted by a lower proportion of patients using analgesics in the fibrin group over the study duration (

177 However, consumption of opioid analgesics in the region is low and data suggest that at

178 dequate staffing ratios; and availability of analgesics, including opioids, for pain relief.

179 ng, and usually refractory to treatment with analgesics, including opioids.

180 om animal and human studies indicates opioid analgesics increase susceptibility to infections, it is

181 Prescriptions for opioid analgesics increased substantially from 2002 through 201

182 investigated if exposure of pregnant rats to analgesics (indomethacin or acetaminophen) affected GC d

183 etween 175 and 1,500 nM, similar to those of analgesics intended to block COX enzymes.

184 understanding of the mechanism of action of analgesics, interindividual variations in responses to a

185 Unintentional overdose involving opioid analgesics is a leading cause of injury-related death in

186 Abuse of prescription opioid analgesics is a serious threat to public health, resulti

187 Use of analgesics is common and is associated with increased ri

188 While the therapeutic effect of opioids analgesics is mainly attributed to micro-opioid receptor

189 Identification of non-narcotic analgesics is of paramount importance.

190 activate arrestin signaling may be effective analgesics lacking dysphoric effects.

191 sants, beta-blockers, anaesthetic agents and analgesics; length of sedation and analgesia and total d

192 ogenomics and how it affects the response to analgesics, mainly opioids, is presented in this article

193 Systemic nonopioid analgesics and adjuvant analgesics may be prescribed to relieve chronic pain and

194 Moreover, they imply that analgesics may have the unwanted side effect of reducing

195 focused on opioid cessation and alternative analgesics may improve the safety and efficiency of elec

196 Such peripheral opioid analgesics may represent alternatives to presently avail

197 We will explore topical analgesics' mechanisms of action and their efficacy as o

198 Worldwide, the use of prescription opioid analgesics more than doubled between 2001 and 2013, with

199 an alignment-rate, pain-intensity and use of analgesics, no significant differences existed between g

200 ated alkaloids have been described as opioid analgesics, no therapeutically relevant properties of co

201 of these patients and the effects of opioid analgesics on mu-opioid receptors.

202 inophen and other potentially opioid-sparing analgesics, on the incidence of postoperative delirium i

203 ence was observed regarding the days free of analgesics or sedatives, the duration of night sleep, an

204 CLINICAL QUESTION Do the benefits of opioid analgesics outweigh the risks in patients with persisten

205 e 2005, especially with regard to control of analgesics (overall decrease of 43% since 2005) and hot-

206 and formulations of six prescription opioid analgesics: oxycodone, hydrocodone, hydromorphone, fenta

207 ng or standing and required more intravenous analgesics (P = 0.001, 0.038, and 0.035, respectively).

208 despite significantly less use of peripheral analgesics (P = 0.019).

209 0.02) and took a significantly lower dose of analgesics (P = 0.02).

210 n endocrine disruptor as reported for fellow analgesics paracetamol and aspirin.

211 Secondary outcomes were use of analgesics, perioperative and postoperative complication

212 Prescription opioid analgesics play an important role in the treatment of po

213 Currently available analgesics poorly serve individuals suffering from chron

214 To the extent that nonopioid analgesics reduce opioid consumption, they may decrease

215 opioid interventions as part of a multimodal analgesics regimen for effective pain management after t

216 eneficial and harmful effects of 4 nonopioid analgesics regimens.

217 Subjects taking analgesics reported slightly higher maximum-pain althoug

218 l catheter combined with systemic multimodal analgesics represents the best combination of safety and

219 atory agents, junctional protein regulators, analgesics, secretagogues, and serotonin antagonists hav

220 The use of analgesics, sedatives, or extubation did not significant

221 for birth gestational age, sex, PMA, dose of analgesics/sedatives (fentanyl, morphine, midazolam), me

222 n and may outweigh the benefits; alternative analgesics should be considered first.

223 ceptor agonists, currently in development as analgesics, should be considered as relapse prevention m

224 Opioid-based analgesics such as buprenorphine and morphine also have

225 Traditional analgesics such as opioids and NSAIDs are also problemat

226 tively modulates the actions of other opioid analgesics, such as fentanyl and methadone.

227 ANCE STATEMENT Commonly used clinical opioid analgesics, such as fentanyl and morphine, can produce h

228 ntinociception.SIGNIFICANCE STATEMENT Opioid analgesics, such as morphine, which target the mu opioid

229 ain conditions, are emerging as non-narcotic analgesics, supporting the repurposing of fingolimod for

230 d that, when controlling for prematurity and analgesics, supportive experiences (e.g., breastfeeding,

231 e or hip and inadequate response to standard analgesics, tanezumab, compared with placebo, resulted i

232 s impacting the translatability of potential analgesics targeting P2X3 receptors.

233 Analgesics targeting the delta-opioid receptor (DOR) may

234 Intervention participants received more analgesics than the controls across the 12 mo.

235 her and be more willing to administer opioid analgesics than were physicians.

236 ion is often required and, in the absence of analgesics that are at least as effective but safer, NSA

237 r the development of peripherally restricted analgesics that control BTP and improve quality of life

238 receive significant amounts of sedatives and analgesics that increase their risk of developing coma a

239 pidemic levels, the identification of opioid analgesics that lack abuse potential may provide a path

240 an efficacious strategy in developing future analgesics that lack abuse potential.

241 The generation of potent opioid analgesics that lack the side effects of traditional opi

242 abuse potential compared with current opioid analgesics that target the mu opioid receptor.

243 f acid and U69593 effects to blockade by two analgesics (the nonsteroidal antiinflammatory drug ketop

244 randomization criteria (i.e. need for opioid analgesics) the patient will be randomized to either ear

245 utic potential in the use of KOR agonists as analgesics; therefore, it may be beneficial to develop K

246 After discharge, parents recorded all analgesics they gave their child as well as pain scores

247 Toward developing new potential analgesics, this first structure-activity relationship s

248 (SCD), for which patients may require opioid analgesics throughout life.

249 e dilemma of prescribing opioid or nonopioid analgesics to chronic pain patients; however, the impact

250 ere between the two extremes in using opioid analgesics to cope with their psychological or spiritual

251 Opiates have long been used as analgesics to relieve pain associated with various medic

252 erapeutic profile, the search for non-opioid analgesics to replace these well-established therapeutic

253 obstacle for effective delivery of potential analgesics to the brain.

254 y and were more willing to administer opioid analgesics to them than to their demographic counterpart

255 of low-dose opioids combined with nonopioid analgesics to treat pain and opioid use disorders.

256 have critiqued their underuse of prescribed analgesics to treat pain in their children after painful

257 eceptor (MOR), the primary target for opioid analgesics, to define a signaling pathway that dynamical

258 s with chronic daily headache and overuse of analgesics, triptans, or other acute headache compounds,

259 Risk factors were preoperative use of strong analgesics, unemployment, postoperative complications, a

260 macological interventions to decrease opioid analgesics use, as they have significant adverse effects

261 The number of adjunct analgesics used postoperatively was greater in the ERAS

262 so controlled for the confounding effects of analgesics used to treat NTG-induced headache.

263 ricyclic antidepressant drugs are first line analgesics used to treat SCI-induced neuropathic pain, b

264 ve complications, procedural time, amount of analgesics used, pain intensity until POD 10, duration o

265 e diversion and abuse of prescription opioid analgesics using data through 2013.

266 d before discharge, and receipt of nonopioid analgesics varied substantially.

267 B(2) receptor (CB(2)) agonists are potential analgesics void of psychotropic effects.

268 Preoperative use of strong analgesics was a risk factor for chronic abdominal pain

269 In an attempt to discover novel analgesics, we combined the approach developed to charac

270 To advance the search for novel analgesics, we have generated a panel of monoclonal anti

271 To identify novel NTS2 selective analgesics, we searched for NTS2 selective nonpeptide co

272 oth short-term and longer-term use of opioid analgesics were associated with hip fracture events.

273 Third-line analgesics were scarce across sites and neuropathologies

274 (anticoagulants, diabetes agents, and opioid analgesics) were implicated in an estimated 59.9% (95% C

275 and required a higher dosage of intravenous analgesics when compared with TPLA.

276 Analgesics which affect prostaglandin (PG) pathways are

277 Despite the skilled use of opioid analgesics, which is crucial to the relief of cancer pai

278 the opioid crisis, we need to discover novel analgesics whose mechanisms do not involve the mu opioid

279 and this enhanced pain may be reduced not by analgesics, whose effectiveness is reduced, but by incre

280 rynantheidine analogs show promise as potent analgesics with a mechanism of action that includes mu o

281 or antidepressants and others (e.g., 8c), as analgesics with a reduced side-effect profile.

282 targets, as illustrated by our unique opioid analgesics with a vastly improved pharmacological profil

283 among patients initiating long-acting opioid analgesics with and without previously reported immunosu

284 ed to the use of analgesics, combinations of analgesics with caffeine, ergotamines, and the triptans.

285 receptors and suggests an approach to potent analgesics with fewer deleterious side effects.

286 receptor agonists may hold potential as new analgesics with fewer liabilities of use.

287 The search for analgesics with fewer side effects and less abuse potent

288 The development of novel analgesics with improved safety profiles to combat the o

289 k for further optimization of fentanyl-based analgesics with improved safety profiles.

290 ng interest in the development of new opioid analgesics with improved therapeutic profiles.

291 In the development of analgesics with mixed-opioid agonist activity, periphera

292 tensive research efforts, the development of analgesics with reduced adverse effects remains a signif

293 ed the promise of these ligands as effective analgesics with reduced liability for adverse effects.

294 arrestin2 might produce improved cannabinoid analgesics with reduced motor suppression.

295 promising lead for the development of opioid analgesics with reduced side effects.

296 ntagonist ligands may emerge as novel opioid analgesics with reduced side effects.

297 promising lead for the development of opioid analgesics with reduced tolerance.

298 vious research has substantiated safe opioid analgesics without abuse liability in primates.

299 tin, have been proposed to be more effective analgesics, without the adverse effects triggered by the

300 Tramadol is one of the most commonly used analgesics worldwide, classified as having a low abuse p